Goldman Sachs Initiates Coverage On Krystal Biotech with Buy Rating, Announces Price Target of $160
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan has initiated coverage on Krystal Biotech (NASDAQ:KRYS) with a Buy rating and set a price target of $160.

November 20, 2023 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Krystal Biotech with a Buy rating and a price target of $160.
The initiation of coverage by Goldman Sachs with a Buy rating typically indicates a positive outlook on the company's future performance. The price target of $160 suggests a significant upside potential from the current trading price, which could lead to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100